Experience

Alkeus Pharmaceuticals, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Member Board of Directors

  • Nov 2022 - 1 year 2 months

  Cambridge, Massachusetts, United States



Aviceda Therapeutics Inc

• Member Board of Directors

  • Jul 2020 - 3 years 6 months

  Cambridge, Massachusetts, United States



Reveal Pharmaceuticals

• United States
• Biotechnology Research
• 1 - 100 Employee

• Member Board of Directors

  • Oct 2022 - 1 year 3 months

  Cambridge, Massachusetts, United States



Cydan II Inc.

• Co-Founder & CEO, Board Member

  • Apr 2014 - Dec 2021

  Cambridge



Tiburio Therapeutics

• Co-Founder & Board Member

  • Oct 2018 - Jan 2019

  Cambridge, Massachusetts


Imara Inc.
• United States
• Biotechnology Research
• 1 - 100 Employee
• Co-Founder

  • Apr 2016 - May 2018


Vtesse Inc.

• United States
• Biotechnology Research

• Founder and Board Member

  • Dec 2013 - Apr 2017

  Gaithersburg, MD



Cydan Development Inc.

• United States
• Pharmaceutical Manufacturing

• Chief Business Officer

  • Jan 2013 - Apr 2014

  Cambridge, MA Cydan, LLC is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. Cydan's model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. The accelerator will focus on identifying promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking… Show more Cydan, LLC is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. Cydan's model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. The accelerator will focus on identifying promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process will enable Cydan to form stand-alone companies and strategic partnerships. The most viable programs will be spun out of the Cydan accelerator as new startup companies focused on making an impact on the lives of patients with rare diseases. Based in Cambridge, Mass., Cydan was launched in 2013 with financing from leading investors NEA, Pfizer Venture Investments, Lundbeckfonds Ventures, Bay City Capital and Alexandria Real Estate Equities. Show less


CMA Biotech Consulting
• President

  • 2012 - Dec 2012

FoldRx Pharmaceuticals
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• Chief Business Officer

  • 2005 - 2011

ViaCell
• Czechia
• Wellness and Fitness Services
• 1 - 100 Employee
• Senior V.P. Business Development

  • 2001 - Jun 2005

Transkaryotic Therapies
• United States
• Medical Practices
• Vice President, Business Development

  • 1994 - 2001

Ciba-Geigy
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• Director Business Development

  • 1991 - 1994

Ciba Geigy Pharma
• International Product Management

  • 1989 - 1991